Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial
Top Cited Papers
- 22 January 2016
- journal article
- research article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 64 (5), 1090-1098
- https://doi.org/10.1016/j.jhep.2016.01.012
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trialJournal of Hepatology, 2012
- The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinomaBMC Cancer, 2012
- Clinical decision making and research in hepatocellular carcinoma: Pivotal role of imaging techniquesHepatology, 2011
- The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinomaAlimentary Pharmacology & Therapeutics, 2011
- Management of hepatocellular carcinoma: An updateHepatology, 2011
- Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V StudyCardioVascular and Interventional Radiology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000